본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Respiratory medicine v.132, 2017년, pp.9 - 14   SCI SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Toxicity risk from glucocorticoids in sarcoidosis patients

Khan, Nauman A. (Department of Hospital Medicine, Cleveland Clinic, USA ) ; Donatelli, Christopher V. (Division of Pulmonary, Critical Care and Sleep Medicine, University Hospitals Cleveland Medical Center, Louis Stoke Cleveland VA Medical Center, Case Western Reserve University, USA ) ; Tonelli, Adriano R. (Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, USA ) ; Wiesen, Jonathan (Community Intensivists Group, Cleveland & Ben Gurion University, Israel ) ; Ribeiro Neto, Manuel L. (Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, USA ) ; Sahoo, Debasis (Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, USA ) ; Culver, Daniel A. (Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, USA ) ;
  • 초록  

    Abstract Background Glucocorticoids (GC) are considered first-line therapy for treating sarcoidosis, but there are few data about the adverse consequences of GC. Although there are several steroid-sparing medications available for treatment, a large proportion of patients are treated with prolonged courses of GC. The toxicities of GC in sarcoidosis populations have not been carefully evaluated. Methods We performed a retrospective cohort study of all newly diagnosed sarcoidosis patients who had the entirety of their medical care in a single health system. We analyzed the time to development of a composite toxicity end-point, including diabetes, hypertension, weight gain, hyperlipidemia, low bone density and ocular complications of GC using Cox proportional hazards analysis. Results One hundred and five patients were ever treated with GC, whereas 49 were not treated during a median follow-up of 101 months. GC-treated patients developed 1.3 ± 1.1 toxicities during therapy, versus 0.6 ± 1.0 in the non-treated group. After adjustment for age, gender, race and preexisting conditions, the hazard ratio for ever-treated patients was 2.37 (1.34–4.17) for the composite end-point. Age and the presence of preexisting conditions also were associated with reaching the end-point. Similar effects were seen when analyzed for cumulative GC dose and for duration of GC use. For individual end-points, weight gain (HR 2.04) and new hypertension (HR 3.36) were associated with any use of GC. Conclusions Our data suggest that GC are associated with clinically important toxicities in sarcoidosis patients, associated with both the cumulative dose and duration of treatment. Highlights Standard therapy of sarcoidosis includes steroids, often in prolonged courses. Long-term steroids for sarcoidosis are associated with significant comorbidity. Steroid therapy in sarcoidosis needs to be re-evaluated and minimized when possible.


  • 주제어

    Sarcoidosis .   Glucocorticoid .   Metabolic syndrome .   Steroid toxicity.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기